The Role of Biomarkers in Clinical Trials
Copthorne Tara Hotel
Scarsdale Place, Kensington, London, W8 5SR
London, United Kingdom
SMi is proud to present their 3rd annual conference on Biomarkers in Clinical Trials. With the 2011 event aiming to explore the use of biomarkers in Cancer drug development.

Concerns over efficacy, cost, and drug safety have stimulated a need for personalized medicine; and to increase the predictability of clinical research to reduce development cost and time. The use of biomarkers in no longer limited to whether a patient will respond to a treatment, but has extended to aid drug development in all its forms.

As a result biomarkers have now gained significant attention in the R&D process. Which are seen as an emerging but lucrative segment that is opening up new development opportunities, and attracting much commercial interest.

The global biomarker market is estimated to be £12.7 billion by 2014, and driven by the high demand for the biomarkers in the field of drug discovery.

In addition the increasing use of biomarkers in clinical services is boosting the overall biomarker service provider market.

    *  A focussed agenda addressing the use of biomarkers in Oncology drug development

    * New developments in Biomarker Validation, Qualification, and Clinical Applications

    * Personalised Medicine and Companion Diagnostics

    * Pharmacology Biomarkers and PK/PD modelling

    * The application of informatics to biomarker usage in clinical trials

Schedule of Presentations:

Monday, September 19, 2011
08:30:00 Registration & Coffee
09:00:00 Chairman's Opening Remarks
09:10:00 Intergrating various fit-for-purpose biomarker studies in oncgology early phase clinical trialsI, their benefits and challenges
09:50:00 Development of oncologymap™ : A public-private partnership dedicated to proviging a powerful new tool for discovery of biomarker patterns in cancer Michael Spain
10:30:00 Morning Coffee
11:00:00 Biomarkers development: Relevance to commercialisation of new products? Lincoln Tsang
11:40:00 Intratumoral immune reaction: a novel paradigm for cancer Jerome Galon
12:20:00 Networking Lunch
13:30:00 Image Analaysis as an enabling technologyfor the development of drug diagnostics
14:10:00 Blockbusters or niche products - the lure of personalised medicine Karol Sikora
14:50:00 Afternoon Tea
15:10:00 Advanced bioinfromatics tools for clincial trials, biomarker discovery to co-therapy management Adam Gouldsworthy
15:50:00 A core microRNA signature of lung inflammation in rat and man Sterghios Moschos
16:30:00 Chairman’s Closing Remarks and Close of Day One
Tuesday, September 20, 2011
08:30:00 Registration & Coffee
09:00:00 Chairman's Opening Remarks Robert Brown
09:10:00 Use of biomarkers as translational sciences and exploratory medicine tools for decision making in drug development
09:50:00 Biomarker for early assessment of response to therapy Rudolf Oehler
10:30:00 Morning Coffee
11:00:00 Forward and reverse translational studies of epigenetic biomarker for old and new drugs Robert Brown
11:40:00 Epigenetic profiling - enabling personalized medicine? Mark Eccleston
12:20:00 Analyses of a biomarker in an oncology phase 2 program Vincent Haddad
13:00:00 Networking Lunch
14:00:00 EU resarch funding towards new pharmacogenomics strategies: examples and success stories Patrik Kolar
14:40:00 Ensuring operational success in implementing and managing biomarkers within oncology clinical trials
15:20:00 Afternoon Tea
15:30:00 Chairman’s Closing Remarks and Close of Day Two Robert Brown
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.